PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
50.36
+0.98 (1.98%)
Feb 5, 2025, 9:54 AM EST - Market open
PTC Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for PTC Therapeutics stock have an average target of 55.62, with a low estimate of 30 and a high estimate of 113. The average target predicts an increase of 10.44% from the current stock price of 50.36.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for PTC Therapeutics stock from 13 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 4 | 5 | 5 | 5 |
| Hold | 5 | 4 | 4 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 3 | 3 | 2 | 2 | 2 | 2 |
| Total | 14 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $76 → $113 | Buy | Maintains | $76 → $113 | +124.38% | Feb 3, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $80 → $76 | Buy | Maintains | $80 → $76 | +50.91% | Jan 15, 2025 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $45 → $67 | Hold → Buy | Upgrades | $45 → $67 | +33.04% | Dec 13, 2024 |
| Citigroup | Citigroup | Strong Sell Maintains $26 → $32 | Strong Sell | Maintains | $26 → $32 | -36.46% | Dec 4, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $32 → $42 | Strong Sell | Maintains | $32 → $42 | -16.60% | Dec 4, 2024 |
Financial Forecast
Revenue This Year
819.80M
from 937.82M
Decreased by -12.58%
Revenue Next Year
932.12M
from 819.80M
Increased by 13.70%
EPS This Year
-4.78
from -8.37
EPS Next Year
-0.70
from -4.78
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 985.5M | 2.3B | 1.2B | |||
| Avg | 819.8M | 932.1M | 899.6M | |||
| Low | 753.6M | 602.7M | 681.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 5.1% | 174.5% | 32.1% | |||
| Avg | -12.6% | 13.7% | -3.5% | |||
| Low | -19.6% | -26.5% | -26.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.08 | 12.60 | 1.23 | |||
| Avg | -4.78 | -0.70 | -1.80 | |||
| Low | -5.93 | -7.45 | -7.22 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.